These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 11153678)

  • 41. Detection of resistant mutations in the reverse transcriptase of HIV-1-infected children.
    Palomares JC; Perea EJ; Terrero E; Torres MJ; García ML; Romero J; Alejo A
    Clin Microbiol Infect; 2000 May; 6(5):268-70. PubMed ID: 11168125
    [No Abstract]   [Full Text] [Related]  

  • 42. Limits of resistance testing.
    D'Aquila RT
    Antivir Ther; 2000 Mar; 5(1):71-6. PubMed ID: 10846596
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Algorithm specification interface for human immunodeficiency virus type 1 genotypic interpretation.
    Betts BJ; Shafer RW
    J Clin Microbiol; 2003 Jun; 41(6):2792-4. PubMed ID: 12791935
    [No Abstract]   [Full Text] [Related]  

  • 44. Primary lamivudine resistance in acute/early human immunodeficiency virus infection.
    Conway B; Montessori V; Rouleau D; Montaner JS; O'Shaughnessy MV; Fransen S; Shillington A; Weislow O; Mayers DL
    Clin Infect Dis; 1999 Apr; 28(4):910-1. PubMed ID: 10825060
    [No Abstract]   [Full Text] [Related]  

  • 45. Transmission of zidovudine resistant strains of HIV-1: the first wave.
    Blower S
    AIDS; 2001 Nov; 15(17):2317-8. PubMed ID: 11698706
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates.
    Vanhems P; Gaudet R; Hirschel B; Imrie A; Conway B; Rouleau D; Vizzard J; Perrin L; Cooper DA; Yerly S
    AIDS; 2000 May; 14(8):1065-7. PubMed ID: 10853993
    [No Abstract]   [Full Text] [Related]  

  • 47. Incomplete genotypic resistance to nonnucleoside reverse transcriptase inhibitors in patients treated with nevirapine: a potential interest in clinical practice.
    Grappin M; Piroth L; Kohli E; Buisson M; Duong M; Chavanet P; Portier H
    J Acquir Immune Defic Syndr; 2000 Dec; 25(5):464-5. PubMed ID: 11141247
    [No Abstract]   [Full Text] [Related]  

  • 48. Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure.
    Briones C; Soriano V; González-Lahoz J
    AIDS; 2000 Jul; 14(11):1659-60. PubMed ID: 10983655
    [No Abstract]   [Full Text] [Related]  

  • 49. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of drug-selected mutations in HIV-1 subtype E reverse transcriptase sequence using the line probe assay.
    Lee CC; Thoe SY; Leo YS; Chan KP; Ling AE
    AIDS; 2000 May; 14(8):1064-5. PubMed ID: 10853992
    [No Abstract]   [Full Text] [Related]  

  • 51. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 52. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.
    Van Laethem K; Witvrouw M; Pannecouque C; Van Remoortel B; Schmit JC; Esnouf R; Kleim JP; Balzarini J; Desmyter J; De Clercq E; Vandamme AM
    AIDS; 2001 Mar; 15(5):553-61. PubMed ID: 11316991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced antiretroviral drug susceptibility among patients with primary HIV infection.
    Little SJ; Daar ES; D'Aquila RT; Keiser PH; Connick E; Whitcomb JM; Hellmann NS; Petropoulos CJ; Sutton L; Pitt JA; Rosenberg ES; Koup RA; Walker BD; Richman DD
    JAMA; 1999 Sep 22-29; 282(12):1142-9. PubMed ID: 10501117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B.
    Grossman Z; Vardinon N; Chemtob D; Alkan ML; Bentwich Z; Burke M; Gottesman G; Istomin V; Levi I; Maayan S; Shahar E; Schapiro JM;
    AIDS; 2001 Aug; 15(12):1453-60. PubMed ID: 11504976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
    Wirden M; Delaugerre C; Marcelin AG; Ktorza N; Ait Mohand H; Dominguez S; Schneider L; Ghosn J; Pauchard M; Costagliola D; Katlama C; Calvez V
    Antimicrob Agents Chemother; 2004 Feb; 48(2):644-7. PubMed ID: 14742228
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective expansion of a minor proportion of drug-resistant HIV-1 by antiretroviral pressure in vitro.
    Roberts BD; Pau CP; Weinstock H; Heneine W; Butera ST
    AIDS; 2000 Dec; 14(17):2797-8. PubMed ID: 11125904
    [No Abstract]   [Full Text] [Related]  

  • 60. Interpretation of resistance assay results.
    Miller V
    Antivir Ther; 2001; 6 Suppl 2():1-9. PubMed ID: 11678473
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.